{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T18:52:49Z","timestamp":1773600769266,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jad.2022.02.002","type":"journal-article","created":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T02:38:14Z","timestamp":1644028694000},"page":"123-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Vortioxetine 5, 10, and 20 mg significantly reduces the risk of relapse compared with placebo in patients with remitted major depressive disorder: The RESET study"],"prefix":"10.1016","volume":"303","author":[{"given":"Michael E.","family":"Thase","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula L.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rengyi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Tolkoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naga Venkatesha","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2022.02.002_bib0001","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1017\/S1461145711001027","article-title":"A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder","volume":"15","author":"Alvarez","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2022.02.002_bib0002","unstructured":"American Psychiatric Association. 2010. Practice guideline for the treatment of patients with major depressive disorder. 3rd edition. October 2010. https:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/mdd.pdf (accessed February 19, 2021)."},{"key":"10.1016\/j.jad.2022.02.002_bib0003","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jad.2016.07.015","article-title":"A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms","volume":"206","author":"Baldwin","year":"2016","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2022.02.002_bib0004","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/jm101459g","article-title":"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder","volume":"54","author":"Bang-Andersen","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jad.2022.02.002_bib0005","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4088\/JCP.13r08722","article-title":"Review of maintenance trials for major depressive disorder: a 25-year perspective from the US Food and drug administration","volume":"75","author":"Borges","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2022.02.002_bib0006","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1177\/0269881112441866","article-title":"A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder","volume":"26","author":"Boulenger","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2022.02.002_bib0007","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jad.2020.01.090","article-title":"A novel study design for investigating relapse prevention in major depressive disorder: preliminary data from the open-label period of a phase 4 vortioxetine study","volume":"266","author":"Jacobsen","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2022.02.002_bib0008","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/YIC.0000000000000081","article-title":"Safety and tolerability of vortioxetine (15 and 20\u2009mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study","volume":"30","author":"Jacobsen","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2022.02.002_bib0009","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cct.2017.07.021","article-title":"Differing antidepressant maintenance methodologies","volume":"61","author":"Safer","year":"2017","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.jad.2022.02.002_bib0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","article-title":"Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data","volume":"145","author":"Sanchez","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jad.2022.02.002_bib0011","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/jcph.689","article-title":"Mitigating the effects of nonadherence in clinical trials","volume":"56","author":"Shiovitz","year":"2016","journal-title":"J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.jad.2022.02.002_bib0012","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1017\/S1092852900015212","article-title":"Preventing relapse and recurrence of depression: a brief review of therapeutic options","volume":"11","author":"Thase","year":"2006","journal-title":"CNS. Spectr."},{"key":"10.1016\/j.jad.2022.02.002_bib0013","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.euroneuro.2016.03.007","article-title":"A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults","volume":"26","author":"Thase","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2022.02.002_bib0014","series-title":"(Vortioxetine) [prescribing information]","year":"2021"},{"key":"10.1016\/j.jad.2022.02.002_bib0015","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.euroneuro.2017.06.012","article-title":"Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder","volume":"27","author":"Vieta","year":"2017","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032722001380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032722001380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T02:46:37Z","timestamp":1759027597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032722001380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":15,"alternative-id":["S0165032722001380"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2022.02.002","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vortioxetine 5, 10, and 20 mg significantly reduces the risk of relapse compared with placebo in patients with remitted major depressive disorder: The RESET study","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2022.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}